In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance

Yuao Zhu; Irina Yurgelonis; Stephen Noell; Qingyi Yang; Shunjie Guan; Zheng-Hui Li; Li Hao; Hussin A. Rothan; K. Devendra; Patricia McMonagle; Mary Lynn Baniecki; S.E. Greasley; Olga Plotnikova; Jonathan Lee; Jennifer Nicki; Rose Ann Ferre; Laura J. Byrnes; Wei Liu; Timothy K. Craig; Claire M. Steppan; Paul Liberator; Holly Soares; Charlotte Allerton; Annaliesa S. Anderson; Rhonda D. Cardin

doi:10.1126/sciadv.adl4013

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

To facilitate the detection and management of potential clinical antiviral resistance, in vitro selection of drug-resistant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) against the virus M

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhu et al. (2024) studied this question.

synapsesocial.com/papers/68e5f2d2b6db643587587583 https://doi.org/10.1126/sciadv.adl4013

View Full Paper

Ask AI

Bookmark

Share

In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance

Ask about this paper

Abstract

Discussion

Cite This Study

In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading